This CPB has been revised to state that bortezomib is considered medically necessary for the following indications: 1) primary cutaneous anaplastic large cell lymphoma (ALCL) with multifocal lesions; 2) cutaneous ALCL with regional nodes; and 3) mantle cell lymphoma, without regard to line of treatment. This CPB is revised to state that bortezomib is considered experimental and investigational for autoimmunity in children, hepatocellular carcinoma, hyper IgG4 syndrome, myasthenia gravis, and systemic ALCL.